Coherus BioSciences, Inc. (CHRS): Price and Financial Metrics

CHRS POWR Grades

• Value is the dimension where CHRS ranks best; there it ranks ahead of 87.36% of US stocks.
• CHRS's strongest trending metric is Growth; it's been moving up over the last 179 days.
• CHRS's current lowest rank is in the Sentiment metric (where it is better than 3.74% of US stocks).

CHRS Stock Summary

• With a one year PEG ratio of 1.28, Coherus BioSciences Inc is expected to have a higher PEG ratio (a measure of how expensive a stock is relative to its expected earnings growth) than just 6.36% of US stocks.
• Over the past twelve months, CHRS has reported earnings growth of -268.38%, putting it ahead of merely 7.23% of US stocks in our set.
• Revenue growth over the past 12 months for Coherus BioSciences Inc comes in at -31.37%, a number that bests only 5.34% of the US stocks we're tracking.
• If you're looking for stocks that are quantitatively similar to Coherus BioSciences Inc, a group of peers worth examining would be AGLE, MCRB, CRIS, VYGR, and SURF.
• CHRS's SEC filings can be seen here. And to visit Coherus BioSciences Inc's official web site, go to www.coherus.com.

CHRS Valuation Summary

• CHRS's price/sales ratio is 3.1; this is 18.42% lower than that of the median Healthcare stock.
• Over the past 83 months, CHRS's price/sales ratio has gone down 12.5.
• Over the past 83 months, CHRS's price/sales ratio has gone down 12.5.

Below are key valuation metrics over time for CHRS.

CHRS Growth Metrics

Its 4 year price growth rate is now at -13.23%.
• Its year over year net cashflow from operations growth rate is now at 43.74%.
• The 3 year price growth rate now stands at -16.15%.

Over the past 34 months, CHRS's revenue has gone up $289,453,000.

The table below shows CHRS's growth in key financial areas (numbers in millions of US dollars).

Date	Revenue	Operating Cash Flow	Net Income to Common Stock
2021-12-31	326.551	-37.432	-287.1
2021-09-30	363.599	48.014	-231.667
2021-06-30	394.647	81.656	-165.206
2021-03-31	442.678	142.035	-76.275
2020-12-31	475.824	154.145	132.244
2020-09-30	489.261	138.731	161.763

CHRS's Quality Factors

The “Quality” component of the POWR Ratings focuses on 31 different factors of a companies fundamentals and operational strength. Here are some key insights as we drill into the specifics of these quality attributes.

• CHRS has a Quality Grade of B, ranking ahead of 82.07% of graded US stocks.
• CHRS's asset turnover comes in at 0.513 -- ranking 78th of 682 Pharmaceutical Products stocks.
• CPRX, XTNT, and VIVO are the stocks whose asset turnover ratios are most correlated with CHRS.

The table below shows CHRS's key quality metrics over time.